AI imaging interpreter gains FDA’s OK for prostate care

The FDA has cleared an AI tool that helps radiologists diagnose or rule out prostate cancer on MRI scans.

Valencia, Spain-based Quibim says its qp-Prostate product extracts quantitative imaging data in key regions of and around the gland, which can cut a radiologist’s reading time while augmenting his or her visual inspection.

The company suggests such augmentation can facilitate early detection and avoid invasive biopsies and unnecessary surgeries.

Quibim notes prostate cancer hits 1.4 million men each year and is the second most common cancer in men, behind only skin cancer.

Announcement here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.